| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Naringin inhibits the activation of the NF-κ B signaling pathway. In HBZY-1 cells, naringenin prevents oxidative stress injury, inflammatory response, and proliferation brought on by high glucose[1]. AGS cancer cell growth is inhibited by naringin in a time- and dose-dependent way. In Naringin-treated AGS cells, phosphorylation of PI3K and its activated downstream targets, p-Akt and p-mTOR, is markedly reduced at 2 mM. In AGS cells, naringin causes autophagic cell death. In AGS cells, naringin triggered the autophagy-related protein[2]. PC12 cells are shielded from 3-NP neurotoxicity by naringin. When 3-NP-induced PC12 cells are treated with naringin, the release of lactate dehydrogenase is reduced. By raising the amount of reduced glutathione and the activities of enzymatic antioxidants, naringin therapy improves antioxidant defense[3].
|
|---|---|
| ln Vivo |
Naringin treatment considerably reduces renal damage in diabetic rats and causes a large rise in body weight. In diabetic rats, naringin administration successfully reduces collagen deposition and renal interstitial fibrosis. Naringin treatment may cause ROS and MDA levels to drop while SOD and GSH-Px activities rise[1]. Naringin administered orally dramatically enhances memory and learning capacities. The insulin signaling pathway is markedly enhanced by naringin[3].
|
| References |
|
| Additional Infomation |
Naringin dihydrochalcone is a member of flavonoids and a glycoside.
|
| Molecular Formula |
C27H34O14
|
|---|---|
| Molecular Weight |
582.5505
|
| Exact Mass |
582.194
|
| CAS # |
18916-17-1
|
| PubChem CID |
9894584
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
916.8±65.0 °C at 760 mmHg
|
| Melting Point |
131-132°C
|
| Flash Point |
302.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.696
|
| LogP |
3.38
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
41
|
| Complexity |
827
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C(C(=C3)O)C(=O)CCC4=CC=C(C=C4)O)O)CO)O)O)O)O)O
|
| InChi Key |
CWBZAESOUBENAP-QVNVHUMTSA-N
|
| InChi Code |
InChI=1S/C27H34O14/c1-11-20(33)22(35)24(37)26(38-11)41-25-23(36)21(34)18(10-28)40-27(25)39-14-8-16(31)19(17(32)9-14)15(30)7-4-12-2-5-13(29)6-3-12/h2-3,5-6,8-9,11,18,20-29,31-37H,4,7,10H2,1H3/t11-,18+,20-,21+,22+,23-,24+,25+,26-,27+/m0/s1
|
| Chemical Name |
1-[4-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~171.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 10 mg/mL (17.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 10 mg/mL (17.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7166 mL | 8.5830 mL | 17.1659 mL | |
| 5 mM | 0.3433 mL | 1.7166 mL | 3.4332 mL | |
| 10 mM | 0.1717 mL | 0.8583 mL | 1.7166 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
